Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer

@article{Zhou2011PhaseIS,
  title={Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer},
  author={Zheng-tao Zhou and Fu-xiang Zhou and Qing Wei and Li-yong Zou and Bin-fang Qin and Xu-shen Peng},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2011},
  volume={68},
  pages={1027-1032}
}
To investigate the efficacy and safety of endostar, a novel recombinant human endostatin, plus cisplatin, and etoposide in patients with extensive-stage small-cell lung cancer (ED-SCLC). Chemotherapy-naïve patients with histologically confirmed, measurable ED-SCLC were enrolled. Treatment consisted of cisplatin (25 mg/m2) administered intravenously (IV) on days 1–3; etoposide (120 mg/m2) administered intravenously (IV) on days 1–3; endostar (15 mg) administered intravenously (IV) on days 1–14… CONTINUE READING
7 Citations
27 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 27 references

the angiogenic phenomenon

  • M Lucchi, A Mussi, Small cell lung carcinoma
  • Eur J Cardiothorac Surg 21:1105–1110 Cancer…
  • 2011
1 Excerpt

CALGB 30306 : a phase II study of cisplatin ( C ) , irinotecan ( I ) and bevacizumab ( B ) for untreated extensive - stage , small - cell lung cancer ( ES - SCLC )

  • AZ Dudek, XF Wang
  • J Clin Oncol
  • 2007

Similar Papers

Loading similar papers…